查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049322

結核病診斷市場規模、佔有率、趨勢和預測：按疾病階段、檢測類型、最終用戶和地區分類，2026-2034 年

Tuberculosis Diagnostics Market Size, Share, Trends and Forecast by Disease Stage, Test Type, End-User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2025年全球結核病診斷市場規模為27億美元。展望未來，IMARC Group預測，該市場將以3.85%的複合年成長率從2026年成長至2034年，到2034年達到39億美元。北美是該市場的主要驅動力，在2025年佔據超過35.7%的市場。先進的醫療保健體系、強力的政府支持、較高的公眾意識以及技術創新是推動結核病診斷市場佔有率成長的部分因素。

全球結核病發生率的不斷上升，尤其是在發展中地區，是推動結核病診斷市場成長的主要因素。分子診斷和核酸增幅檢查等診斷技術的進步，提高了結核病檢測的準確性、速度和靈敏度，從而推動了對創新診斷解決方案的需求。此外，為控制結核病傳播，人們越來越重視早期快速診斷，這也促使自動化系統和數位化平台廣泛應用，以更快獲得檢測結果。政府、非政府組織和世界衛生組織等國際衛生組織對結核病控制計畫的投入不斷增加，進一步促進了結核病診斷市場的成長。大眾對結核病的認知不斷提高，對更高效診斷工具的需求日益成長，以及對綜合醫療保健解決方案的推動，都在促進結核病診斷市場的擴張。

在美國，結核病診斷的最新進展主要集中在檢測流程自動化上，以提高效率。新近獲得FDA核准的平台正在提升檢查室能力，提供更快、更準確的結果，並支持全球控制潛伏性結核病的努力。這些創新簡化了工作流程，同時確保了診斷程序的準確性。例如，Revvity公司於2025年4月獲得了FDA對其Auto-Pure 2400平台的核准，該平台與T-SPOT.TB檢測相結合，可實現潛伏性結核病診斷的自動化和增強。這項核准的解決方案將透過提供準確的結果來提高檢查室能力，並支持全球對抗結核病的努力。

結核病診斷市場趨勢：

結核病基因測序的進步促進了診斷的改進

近年來，結核分枝桿菌分離株基因測序技術的進步顯著推動了結核病診斷市場的復甦。這項技術旨在加速抗藥性分析，並實現更快、更準確的診斷方法。透過識別遺傳標記，定序工作能夠改善臨床決策，並實現更個人化的治療策略。基因測序在結核病監測中日益廣泛的應用，將有助於更深入地了解區域性結核病突變和抗藥性模式。這種分子層面的洞察有望改進診斷工具，從而實現結核病的早期發現和更有效的治療。基因測序的持續進步有望徹底改變結核病的診斷方式，提高治療效果，並協助實現全球根除結核病的目標。例如，截至2025年3月，印度已基因測序，這是「Dare2eraD TB」計畫的一部分，該計畫旨在提前實現世界衛生組織設定的2030年根除結核病的目標。這項突破性成果將提升結核病診斷水平，加速抗藥性分析，並改善治療效果。該舉措由生物技術部 (DBT)、科學與工業研究理事會 (CSIR) 和印度醫學研究理事會 (ICMR)主導，計劃對超過 32,000 個分離株定序，預計將徹底改變結核病監測和臨床決策。

人們越來越關注耐多藥結核病，這推動了診斷技術的創新。

多重抗藥性結核病（MDR-TB）和利福平抗藥性結核病（RR-TB）的日益普及對結核病診斷市場產生了重大影響。由於這些抗藥性菌株持續在全球造成大量死亡，因此迫切需要先進的診斷解決方案來快速準確地識別這些感染疾病。多重抗藥性結核病對異煙肼和利福平等主要抗生素具有抗藥性，這凸顯了快速抗藥性檢測和分析的重要性。早期準確識別抗藥性菌株的需求推動了對更先進的診斷工具（例如分子和基因組檢測）的需求，以便指南抗藥性模式並指導治療策略。抗藥性結核病菌株的出現正在促進開發更好、更快速的診斷方法，以改善治療效果並降低死亡率。根據世界衛生組織估計，2023年多重抗藥性結核病和利福平抗藥性結核病將導致全球15萬人死亡。多重抗藥性結核病是由對異煙肼和利福平抗藥性的細菌引起的，而異煙肼和利福平被認為是治療結核病最有效的抗生素。

結核病根除宣傳活動提高了診斷需求

印度國家結核病根除計畫（NTEP）在全國範圍內開展的結核病根除宣傳活動對結核病診斷產業產生了重大影響。這項涵蓋全國眾多地區的計畫旨在透過廣泛的篩檢活動來加強結核病的檢測和治療。這項大規模宣傳活動推動了對能夠有效識別潛伏性和活動性結核病病例的快速、準確的診斷工具的需求。由於該計劃強調早期診斷和減少結核病感染，因此對分子診斷和快速檢測等先進診斷解決方案的需求日益成長。結核病診斷市場預測，擴大檢測基礎設施並專注於及時干預將進一步加速創新結核病診斷技術的應用，最終有助於改善結核病控制並加快治療效果。例如，2024年12月，印度國家結核病根除計畫（NTEP）在33個邦和聯邦屬地的347個地區啟動了「百日結核病根除宣傳活動」。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球結核病診斷市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依疾病進展階段分類

  • 潛伏性結核病
  • 活動性肺結核

第7章 市場區隔：依測試類型分類

  • 放射檢查
  • 臨床試驗
    • 主要類型
      • 塗片顯微鏡檢查
      • 培養試驗
  • 核酸檢測
  • 細胞激素檢測
  • 抗藥性檢測
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院和診所
  • 診斷與研究機構
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章 價格指標

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • Alere Inc.
    • Becton Dickinson and Company
    • BioMerieux
    • Cepheid Inc.
    • Epistem Ltd.
    • Roche Holding AG
    • Hain Lifescience GmbH
    • Hologic Inc.
    • QIAGEN GmbH
    • Siemens
    • Thermo Fisher Scientific Inc.
Product Code: SR112026A2047

The global tuberculosis diagnostics market size was valued at USD 2.7 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 3.9 Billion by 2034, exhibiting a CAGR of 3 .85% during 2026-2034. North America dominated the market, holding a significant market share of over 35.7% in 2025 . Advanced healthcare, strong government support, high awareness, and technological innovation are some of the drivers contributing to the tuberculosis diagnostics market share.

The market is primarily driven by the increasing global prevalence of TB, especially in developing regions. Advances in diagnostic technologies, such as molecular and nucleic acid amplification tests, have improved accuracy, speed, and sensitivity in detecting TB, which has boosted demand for innovative diagnostic solutions. Additionally, the rising emphasis on early and rapid diagnosis to control the spread of TB has led to the adoption of automated systems and digital platforms for faster results. Government initiatives, along with support from NGOs and global health organizations like the WHO, are increasing funding for TB control programs, further driving tuberculosis diagnostics market growth. Growing awareness about TB, the need for more efficient diagnostic tools, and the push for integrated healthcare solutions have all contributed to the expansion of the TB diagnostics market.

In the United States, recent advancements in tuberculosis diagnostics focus on automating testing processes to increase efficiency. New FDA-approved platforms are improving lab throughput, delivering faster and more accurate results, and supporting global efforts to control latent tuberculosis. These innovations are streamlining workflows while ensuring precision in diagnostic procedures. For instance, in April 2025, Revvity secured FDA approval for its Auto-Pure 2400 platform integrated with the T-SPOT.TB test to automate and enhance latent tuberculosis diagnostics. The approved solution enables higher lab throughput with accurate results, aiding global tuberculosis control efforts.

TUBERCULOSIS DIAGNOSTICS MARKET TRENDS:

Advancements in TB Genome Sequencing for Enhanced Diagnostics

Recent advancements in genome sequencing of Mycobacterium tuberculosis isolates are significantly enhancing the tuberculosis diagnostics market. This initiative aims to accelerate resistance profiling, enabling faster and more accurate diagnostic methods. By identifying genetic markers, the sequencing efforts improve clinical decision-making and allow for more personalized treatment strategies. The expanded use of genome sequencing in TB surveillance will provide a deeper understanding of regional TB variations and drug resistance patterns. These molecular insights are expected to refine diagnostic tools, enabling quicker detection and more effective management of TB. The ongoing developments in genome sequencing are set to revolutionize TB diagnostics, supporting efforts to improve treatment outcomes and meet global TB elimination targets. For example, as of March 2025, India has completed genome sequencing of 10,000 Mycobacterium tuberculosis isolates as part of the Dare2eraD TB program, aiming to eliminate tuberculosis ahead of the WHO's 2030 targets. This breakthrough will enhance TB diagnostics, speed up resistance profiling, and improve treatment outcomes. The initiative, led by DBT, CSIR, and ICMR, is set to sequence over 32,000 isolates, revolutionizing TB surveillance and clinical decision-making.

Rising Concern of Multidrug-Resistant TB Driving Diagnostic Innovation

The increasing prevalence of multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant tuberculosis (RR-TB) is significantly impacting the tuberculosis diagnostics market outlook. As these drug-resistant strains continue to cause a high number of global deaths, there is an urgent need for advanced diagnostic solutions to identify these infections quickly and accurately. The challenge posed by MDR-TB, which resists treatment with key antimicrobial drugs like isoniazid and rifampicin, highlights the importance of rapid resistance detection and profiling. This need for early and precise identification of resistant strains is driving demand for more sophisticated diagnostic tools, such as molecular and genomic testing, that can detect resistance patterns and guide treatment strategies. The rise of resistant TB strains is pushing the development of better, faster diagnostic methods to improve treatment outcomes and reduce mortality rates. According to WHO, multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant tuberculosis (RR-TB) caused an estimated 150,000 deaths globally in 2023. MDR tuberculosis is caused by bacteria that are resistant to isoniazid and rifampicin, which are considered to be among the most potent antimicrobial drugs for TB.

National TB Elimination Campaign Boosting Diagnostic Demand

The launch of a nationwide TB elimination campaign under India's National TB Elimination Programme (NTEP) is significantly impacting the tuberculosis diagnostics industry. The initiative, covering numerous districts across the country, aims to enhance TB detection and treatment through widespread screening efforts. This large-scale campaign increases the demand for rapid and accurate diagnostic tools that can identify both latent and active TB cases efficiently. As the program focuses on early diagnosis and reducing TB transmission, the need for advanced diagnostic solutions, such as molecular and rapid testing methods, has risen. Tuberculosis diagnostics market forecast suggests that the expansion of testing infrastructure and focus on timely intervention will further drive the adoption of innovative TB diagnostics technologies, ultimately contributing to improved TB control and faster treatment response. For instance, in December 2024, a 100-Day TB Elimination Campaign was launched under the National TB Elimination Programme (NTEP) in India, spanning across spanning 347 districts across 33 states and union territories.

TUBERCULOSIS DIAGNOSTICS INDUSTRY SEGMENTATION:

Analysis by Disease Stage:

  • Latent TB
  • Active TB

Latent TB refers to individuals who have the bacteria in their body but are not showing symptoms, and while they are not contagious, they have a higher risk of developing active TB later. As awareness about the potential progression from latent to active TB increases, there is a growing demand for diagnostic tools that can detect latent infections early. This push for early detection through screening programs, especially in high-risk populations, is fueling the market's growth. Active TB, characterized by symptoms and infectiousness, requires immediate detection and treatment to curb its spread. With the global rise in TB cases, there is a significant demand for rapid diagnostic solutions, such as molecular tests, PCR-based diagnostics, and culture methods, that can quickly and accurately identify active infections. These advancements in TB diagnostics are supporting the market's expansion.

Analysis by Test Type:

  • Radiographic Test
  • Laboratory Test
    • Smear Microscopy
    • Culture-based Test
  • Nucleic Acid Testing
  • Cytokine Detection Test
  • Drug Resistance Test
  • Others

Nucleic acid testing led the market in 2025 due to its ability to provide rapid, accurate, and highly sensitive results. NAT, including polymerase chain reaction (PCR) and other molecular tests, allows for the detection of Mycobacterium tuberculosis DNA in patient samples, making it particularly effective for diagnosing both latent and active TB infections. The speed and precision of NAT reduce diagnostic delays, improving treatment outcomes and limiting the spread of TB. As the demand for quicker, more reliable diagnostic solutions grows, particularly in high-burden regions, NAT continues to gain traction. Furthermore, the ability to detect drug-resistant TB strains through NAT is increasingly crucial, driving further adoption and market growth in efforts to control TB more effectively.

Analysis by End-User:

  • Hospitals and Clinics
  • Diagnostics and Research Laboratories
  • Others

Diagnostics and research laboratories led the market in 2025, holding around 53.2% of the market. These laboratories are central to the development and implementation of advanced diagnostic technologies, such as molecular tests, PCR, and culture-based methods. They provide critical infrastructure for accurate TB detection, offering a variety of testing services for both latent and active TB. With increasing research efforts to develop more efficient, faster, and cost-effective diagnostic tools, these laboratories are at the forefront of innovation in the TB diagnostics market. Additionally, as the demand for accurate and timely diagnosis grows, particularly in TB-endemic regions, the expansion of diagnostics and research laboratories to meet these needs is driving market growth. The continuous advancements and high demand for testing solutions in these settings support the overall market expansion.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 35.7%, owing to its advanced healthcare infrastructure, which ensures widespread access to high-quality diagnostic tools and services. The region benefits from strong government support, with initiatives like the Centers for Disease Control and Prevention (CDC) working toward improving TB detection, treatment, and prevention. Increased awareness of TB and its risks among the population, coupled with substantial investment in healthcare research and development, contributes to the market's growth. Additionally, the presence of leading diagnostic companies and technological innovations, such as molecular diagnostics and automated systems, further enhances TB detection accuracy and speed. These factors combined position North America as a major player in the global TB diagnostics market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET ANALYSIS

In 2025, the United States accounted for 88.7% of the market share in North America. The United States is witnessing increased tuberculosis diagnostics adoption due to the rising prevalence of multi-drug resistant (MDR) tuberculosis. For instance, during 2023, at the time of initial diagnosis, 589 (8.5%) tuberculosis cases in the United States were found to have resistance to at least isoniazid, including 100 (1.4%) cases of multidrug-resistant tuberculosis (MDR TB). The growing burden of MDR strains is compelling healthcare providers to implement more robust and early-stage diagnostic solutions. Enhanced government support, coupled with an expanding network of diagnostic laboratories, is contributing to the prioritization of efficient tuberculosis detection. The focus on MDR tuberculosis is prompting strategic investments in molecular and culture-based diagnostics. In addition, public health campaigns are raising awareness, leading to increased screening rates across high-risk populations. Technological advancements and ongoing clinical research for rapid MDR identification further accelerate the demand for accurate tuberculosis diagnostics.

ASIA PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET ANALYSIS

Asia Pacific is experiencing growing tuberculosis diagnostics adoption driven by expanding diagnostics facilities across the region. For instance, industry experts estimate that, as of February 2025, there are around 3,00,000 labs across India, and this number is growing. With national healthcare systems scaling their capabilities, there is greater access to modern diagnostic tools, enabling early identification and management of tuberculosis cases. The proliferation of public-private partnerships is boosting diagnostic infrastructure in both urban and rural areas. Government initiatives to strengthen infectious disease detection are encouraging hospitals and clinics to adopt updated tuberculosis diagnostics. Expanding laboratory networks, integration of automated testing systems, and capacity building for healthcare professionals are key contributors to this trend. In addition, rising health awareness among populations and improved patient outreach have enhanced participation in tuberculosis screening programs. The increase in diagnostic facilities supports timely intervention and reduces transmission risks, underscoring the importance of structured healthcare delivery in tuberculosis management across Asia Pacific.

EUROPE TUBERCULOSIS DIAGNOSTICS MARKET ANALYSIS

Europe is seeing heightened tuberculosis diagnostics adoption influenced by the rising geriatric population. In the WHO European Region, in 2023, more than 172,000 individuals with new and relapsed tuberculosis were reported, reflecting numbers similar to those seen in 2022. As older adults are more susceptible to infectious diseases due to weakened immunity, tuberculosis screening and diagnostic measures are becoming essential in elderly care. Healthcare systems are incorporating tuberculosis testing into routine evaluations for seniors, particularly in long-term care settings. With aging populations concentrated in urban centers, diagnostic services are being tailored to accommodate this demographic. Innovations in non-invasive testing and mobile diagnostic units are facilitating access for older patients. The growing burden of age-related comorbidities increases the demand for precise and early detection tools. Policymakers are integrating tuberculosis diagnostics into geriatric health strategies, emphasizing preventative care.

LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET ANALYSIS

Latin America is witnessing increased tuberculosis diagnostics adoption due to the expansion of healthcare facilities and privatization. The Brazilian Federation of Hospitals (FBH) and the National Confederation of Health (CNSaude) report that 62% of Brazil's 7,191 hospitals are privately owned. The region is investing in modern medical infrastructure, resulting in enhanced diagnostic capabilities. Privatized healthcare models are introducing competitive, patient-centric services that prioritize accurate tuberculosis detection. New diagnostic centers and private clinics are improving access and efficiency in early-stage tuberculosis testing.

MIDDLE EAST AND AFRICA TUBERCULOSIS DIAGNOSTICS MARKET ANALYSIS

The Middle East and Africa are recording growth in tuberculosis diagnostics adoption driven by increasing healthcare expenditure. For instance, in 2021, the overall prevalence of latent tuberculosis infection (LTBI) in the MENA region was determined to be 41.78%. In gender-specific subgroup analyses, the LTBI prevalence was 33.12% in males and 32.65% in females. The government and private sectors are investing heavily in healthcare infrastructure, leading to greater availability of diagnostic tools. Rising financial commitment is enabling the procurement of advanced equipment and training of professionals in tuberculosis testing.

COMPETITIVE LANDSCAPE:

The tuberculosis diagnostics market is witnessing significant advancements through various avenues, including product launches, partnerships, funding, government initiatives, and research and development. Companies are focusing on introducing innovative diagnostic tools, while collaborations between organizations aim to enhance treatment and diagnostic capabilities. Increased funding is being directed toward the development of advanced diagnostics, particularly for drug-resistant strains. Government initiatives, such as national programs and free diagnostics, are crucial for broadening access to care. Research efforts are geared toward improving and standardizing diagnostic technologies. Currently, government initiatives and partnerships are the most common practices, reflecting a collaborative approach to tackling tuberculosis through better diagnostic solutions.

The report provides a comprehensive analysis of the competitive landscape in the tuberculosis diagnostics market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Alere Inc.
  • Becton Dickinson and Company
  • BioMerieux
  • Cepheid Inc.
  • Epistem Ltd.
  • Roche Holding AG
  • Hain Lifescience GmbH
  • Hologic Inc.
  • QIAGEN GmbH
  • Siemens
  • Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

1. How big is the tuberculosis diagnostics market?

2. What is the future outlook of tuberculosis diagnostics market?

3. What are the key factors driving the tuberculosis diagnostics market?

4. Which region accounts for the largest tuberculosis diagnostics market share?

5. Which are the leading companies in the global tuberculosis diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Tuberculosis Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Stage

  • 6.1 Latent TB
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Active TB
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Test Type

  • 7.1 Radiographic Test
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Laboratory Test
    • 7.2.1 Market Trends
    • 7.2.2 Major Types
      • 7.2.2.1 Smear Microscopy
      • 7.2.2.2 Culture-based Test
    • 7.2.3 Market Forecast
  • 7.3 Nucleic Acid Testing
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cytokine Detection Test
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Drug Resistance Test
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End-User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics and Research Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Alere Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Becton Dickinson and Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 BioMerieux
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Cepheid Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 SWOT Analysis
    • 14.3.6 Epistem Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Roche Holding AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Hain Lifescience GmbH
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Hologic Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 QIAGEN GmbH
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 Siemens
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Thermo Fisher Scientific Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Tuberculosis Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Tuberculosis Diagnostics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Tuberculosis Diagnostics Market: Breakup by Disease Stage (in %), 2025
  • Figure 4: Global: Tuberculosis Diagnostics Market: Breakup by Test Type (in %), 2025
  • Figure 5: Global: Tuberculosis Diagnostics Market: Breakup by End-User (in %), 2025
  • Figure 6: Global: Tuberculosis Diagnostics Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Tuberculosis Diagnostics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Tuberculosis Diagnostics (Latent TB) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Tuberculosis Diagnostics (Latent TB) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Tuberculosis Diagnostics (Active TB) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Tuberculosis Diagnostics (Active TB) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Tuberculosis Diagnostics (Radiographic Test) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Tuberculosis Diagnostics (Radiographic Test) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Tuberculosis Diagnostics (Laboratory Test) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Tuberculosis Diagnostics (Laboratory Test) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Tuberculosis Diagnostics (Nucleic Acid Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Tuberculosis Diagnostics (Nucleic Acid Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Tuberculosis Diagnostics (Cytokine Detection Test) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Tuberculosis Diagnostics (Cytokine Detection Test) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Tuberculosis Diagnostics (Drug Resistance Test) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Tuberculosis Diagnostics (Drug Resistance Test) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Tuberculosis Diagnostics (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Tuberculosis Diagnostics (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Tuberculosis Diagnostics (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Tuberculosis Diagnostics (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Tuberculosis Diagnostics (Diagnostics and Research Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Tuberculosis Diagnostics (Diagnostics and Research Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Tuberculosis Diagnostics (Other End-Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Tuberculosis Diagnostics (Other End-Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: North America: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: North America: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: United States: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: United States: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Canada: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Canada: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Asia Pacific: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Asia Pacific: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: China: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: China: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Japan: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Japan: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: India: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: India: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: South Korea: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: South Korea: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Australia: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Australia: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Indonesia: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Indonesia: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Others: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Others: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Europe: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Europe: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Germany: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Germany: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: France: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: France: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: United Kingdom: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: United Kingdom: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Italy: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Italy: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Spain: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Spain: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Russia: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Russia: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Others: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Others: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Latin America: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Latin America: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Brazil: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Brazil: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Mexico: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Mexico: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Others: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Others: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Middle East and Africa: Tuberculosis Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Middle East and Africa: Tuberculosis Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Global: Tuberculosis Diagnostics Industry: SWOT Analysis
  • Figure 79: Global: Tuberculosis Diagnostics Industry: Value Chain Analysis
  • Figure 80: Global: Tuberculosis Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Tuberculosis Diagnostics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Tuberculosis Diagnostics Market Forecast: Breakup by Disease Stage (in Million USD), 2026-2034
  • Table 3: Global: Tuberculosis Diagnostics Market Forecast: Breakup by Test Type (in Million USD), 2026-2034
  • Table 4: Global: Tuberculosis Diagnostics Market Forecast: Breakup by End-User (in Million USD), 2026-2034
  • Table 5: Global: Tuberculosis Diagnostics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Tuberculosis Diagnostics Market: Competitive Structure
  • Table 7: Global: Tuberculosis Diagnostics Market: Key Players